Searched for
INSULIN LISPRO
Trump launches TrumpRx: New government portal promises up to 80% off prescription drug pricesTrumpRx is a new government portal launched by Donald Trump to help people save money on prescription drugs. The site lists cash discounts ...- Trump govt rolls out TrumpRx website for discounted drugs, Americans to get massive relief on prices of major medicines, Bevespi Aerosphere and Ozempic on the list; check pricesThe Trump administration launched TrumpRx.gov on Thursday (February 5, 2026), a website designed to help Americans purchase prescription dr...
- Habil Khorakiwala on 3 things in the pipeline that can cause a re-rating for WockhardtHabil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to m...
- Amazon Pharmacy automates discounts to help insulin patients get pledged pricesWith the new program, patients using Amazon Pharmacy will no longer have to search for and manually enter coupons from the three largest in...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- Will PLI help Indian pharma gain market share at cost of MNCs?Indian pharmaceutical companies are becoming more aggressive and increasing their market share and capex. Companies such as Divis, Dr Reddy...
- Lupin, Eli Lilly join hands for insulin launchLupin said it will market Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.
- Lupin partners Eli Lilly to market diabetes drug 'Eglucent'According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for m...
- Biocon Inks Pact with Mylan for generic insulinIn 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.
- Biocon looking at new global partnerships for its biosimilarsBiocon is now exploring new partnerships with pharma companies for its biosimilars, or low-cost copies of biotechnology products.
- Biocon to focus on regional allies for commercialisationBiocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...
- Biocon hits 52-week low as Pfizer scraps dealBiocon dropped more than 7% early to touch their 52-week low of Rs 238 after Pfizer terminated an agreement to sell insulin products.
- Eli Lilly insulin brand paves way for hike in imported drug pricesThe NPPA will have to increase MRP of US firm Eli Lilly’s insulin brand, paving the way for price increases of other imported medicines who...
- Pfizer deal shot in arm for BioconAs per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...
- Market gives thumbs up to Biocon's deal with PfizerThe Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...
- Biocon seals Rs 1,550 cr pact with PfizerThe agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
Load More
